id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2232-0003,FDA,FDA-2020-E-2232,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-12-14T05:00:00Z,2020,12,2020-12-14T05:00:00Z,,2020-12-14T20:13:59Z,,0,0,090000648499d78c
FDA-2020-E-2232-0001,FDA,FDA-2020-E-2232,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2020-11-25T05:00:00Z,2020,11,2020-11-25T05:00:00Z,,2020-11-25T16:43:02Z,,0,0,09000064849763f6
FDA-2020-E-2232-0002,FDA,FDA-2020-E-2232,"Patent Extension Application from Cooley LLP (on behalf of Ultragenyx Pharmaceutical, Inc.)",Other,Application,2020-11-25T05:00:00Z,2020,11,2020-11-25T05:00:00Z,,2020-11-25T16:43:11Z,,0,0,09000064849763f7